AQST vs. RCUS, CALT, SYRE, SPRY, OCUL, XNCR, ETNB, GYRE, AUPH, and NTLA
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Arcus Biosciences (RCUS), Calliditas Therapeutics AB (publ) (CALT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Ocular Therapeutix (OCUL), Xencor (XNCR), 89bio (ETNB), Gyre Therapeutics (GYRE), Aurinia Pharmaceuticals (AUPH), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.
Aquestive Therapeutics vs.
Arcus Biosciences (NYSE:RCUS) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
Arcus Biosciences has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500.
Aquestive Therapeutics received 17 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 68.17% of users gave Aquestive Therapeutics an outperform vote while only 65.22% of users gave Arcus Biosciences an outperform vote.
Aquestive Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Arcus Biosciences presently has a consensus price target of $29.50, indicating a potential upside of 162.76%. Aquestive Therapeutics has a consensus price target of $11.00, indicating a potential upside of 260.07%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than Arcus Biosciences.
Aquestive Therapeutics has a net margin of -59.75% compared to Arcus Biosciences' net margin of -102.66%. Aquestive Therapeutics' return on equity of 0.00% beat Arcus Biosciences' return on equity.
In the previous week, Arcus Biosciences had 35 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 38 mentions for Arcus Biosciences and 3 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.30 beat Arcus Biosciences' score of 0.09 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.
92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by company insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Aquestive Therapeutics beats Arcus Biosciences on 10 of the 18 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AQST) was last updated on 2/21/2025 by MarketBeat.com Staff
